ArticleFrontiers in immunology2026
Cross-tissue integrative transcriptomic and multimodal analyses suggest shared immune signatures linking lupus nephritis and cutaneous lupus erythematosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) and cutaneous lupus erythematosus (CLE) are major organ manifestations of systemic lupus erythematosus (SLE), imposing significant health and economic burdens due to their chronic course. This study aims to explore putative shared molecular signatures and hypothesis-generating therapeutic targets by examining the expression profiles of genes associated with LN and CLE. Methods: We analyzed gene expression profiles from LN and CLE using bulk transcriptome analysis, single-cell RNA sequencing, and machine learning approaches. Differentially expressed genes (DEGs) were identified, and weighted gene co-expression network analysis (WGCNA) was employed to reveal gene modules associated with clinical traits. Functional enrichment analyses were performed to characterize implicated pathways. Machine learning algorithms, including LASSO, SVM-RFE, and random forest, were applied to screen for putative biomarkers. Single-cell datasets were used to determine the cellular distribution of candidate genes, and validation was conducted in the lupus mouse model C57BL/6-FasLpr. Results: A total of 361 DEGs in LN and 711 DEGs in CLE were identified, with 99 overlapping genes. We combined overlapping genes from WGCNA and DEGs to conducted enrichment analysis, highlighted disease-associated mechanism enriched in immune-related pathways, particularly type I interferon signaling. Machine learning analysis identified six hub genes, PDE4B, ISG20, IFI27, PARP12, IFI44 and GATA3, most of which demonstrated diagnostic value with AUC values >0.7. Single-cell RNA sequencing confirmed their expression in T cells, B cells, and NK cells, implicating them in immune dysregulation. Conclusion: This integrative analysis establishes a shared molecular signature between LN and CLE. The identified hub genes represent promising hypothesis-generating molecular signatures and hypothesis-generating therapeutic targets, with potential to improve risk stratification, guide early intervention, and support precision medicine approaches for lupus comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.